References
- FEUSSNER G: HMG-CoA reductase inhibitors. Curr. Opin, Lipidol. (1994) 5: 59–68.
- SUCKLING KE: Recent developments in hypolipidemic and antlatherosckrotic agents. Curr. Opin. Ther. Patents (1993) 1347–1351.
- BLANKENHORN DH, HODIS HN: Arterial imaging and atherosclerosis reversaL Arteriosclerosis and Thrombosis (1994) 14: 177–192 A thorough review of the field with optimistic conclusions.
- DE FEYTER PJ, DI MARIO C, SERRUYS PW, ROELANDT JRTC: How to assess regression of the atherosclerotic plaque. Biochem. Soci.Transa. (1993) 21: 642–647.
- MARGITIC SE, BOND MG, CROUSE JR, FURBERG CD, PROBSTFIELD JL: Progression and regression of carotid atherosclerosis in clinical trials. Arterio. Thromb. (1991) 11: 443–451
- PARTHASARATHY S, STEINBERG D, WITZTUM JL: The role of oxidised low-density lipoproteins in the pathogene¬ sis of atherosclerosis. AnnMevi. Med. (1992) 43: 219–225 A review by the originators of the concept, of its current status.
- STARY HC, CHANDLER AB, GLAGOV S, GUYTON JR, IN- SULL W, ROSENFELD ME, SCHAFFER SA, SCHWARTZ CJ, WAGNER WD, WISSLER RW: A definition of initial, fatty streak, and Intermediate lesions of atherosclerosis - a report from the Committee on Vascular Lesions of the